Skip to main content

Anavex Life Sciences Corp. (AVXL)

NASDAQ: AVXL · IEX Real-Time Price · USD
17.79
+0.15 (0.85%)
After-hours:Sep 22, 2021 7:34 PM EDT
17.64
0.24 (1.38%)
At close: Sep 22, 4:00 PM
Market Cap1.32B
Revenue (ttm)n/a
Net Income (ttm)-32.16M
Shares Out70.59M
EPS (ttm)-0.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume631,877
Open17.44
Previous Close17.40
Day's Range16.98 - 17.85
52-Week Range3.75 - 31.50
Beta0.71
AnalystsStrong Buy
Price Target38.95 (+120.8%)
Est. Earnings DateDec 27, 2021

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip...

IndustryBiotechnology
CEOChristopher Missling
Employees20
Stock ExchangeNASDAQ
Ticker SymbolAVXL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is 38.95, which is an increase of 120.80% from the latest price.

Price Target
$38.95
(120.80% upside)
Analyst Consensus: Strong Buy

News

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

2 days ago - GlobeNewsWire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

1 month ago - GlobeNewsWire

Use Weakness in these 3 Alzheimer's Disease Stocks as Opportunity

Millions of Americans are struggling with Alzheimer's, according to the Alzheimer's Association. The disease often has a slow progression, lasting years or even decades, and it's one of the leading caus...

Other symbols:ANVSSAVA
1 month ago - InvestorPlace

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

1 month ago - GlobeNewsWire

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Other symbols:ANVSSAVA
1 month ago - The Motley Fool

Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Anim...

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week befo...

1 month ago - Benzinga

Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

1 month ago - Zacks Investment Research

3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021

Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:GTBPSAVA
2 months ago - PennyStocks

Why This Anavex Life Sciences Analyst Is Lifting Their Price Target

A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ:AVXL) after the release of Phase 2 data for the company's lead candidate. The Anavex Analyst: Charles...

2 months ago - Benzinga

Anavex Life Sciences Stock Rallies: Technical Levels To Watch

Anavex Life Sciences Corp. (NASDAQ: AVXL) shares traded higher Monday after the company announced ANAVEX2-73, the company's main pipeline drug, improved both primary cognitive and secondary MDS-UPDRS ef...

2 months ago - Benzinga

7 Hot Penny Stocks Analysts Like To Watch In 2021

Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

2 months ago - PennyStocks

Why Anavex Life Sciences Shares Are Up 17% Today

The biopharma developer dropped some big (but mostly expected) news about the success of one of its drugs.

2 months ago - The Motley Fool

Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's ...

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patien...

2 months ago - Benzinga

3 Top Biotech Stocks to Buy Right Now

These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.

Other symbols:MNOVTARS
2 months ago - The Motley Fool

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

2 months ago - GlobeNewsWire

Why Anavex Life Sciences Blasted Higher Today

The good news keeps coming for one of the biotech's pipeline drugs.

3 months ago - The Motley Fool

Anavex Life's Rett Syndrome Candidate Shows Promising Biomarker Correlating Efficacy Data

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported a predictive biomarker response from its Phase 2 trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. Data showed that AN...

3 months ago - Benzinga

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Con...

ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints RSBQ...

3 months ago - GlobeNewsWire

Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options

Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Why Anavex Life Sciences Stock Soared 35% Today

Research published in a medical journal provides enormous hope for the company's pipeline Alzheimer's drug.

3 months ago - The Motley Fool

Why Anavex Shares Are Surging Today

Anavex Life Sciences Corp (NASDAQ:AVXL) shares are trading higher by 25.7% at $19.49 after the company highlighted ANAVEX 2-73 and ANAVEX3-71 for Alzheimer's were featured in the journal of Expert Opini...

3 months ago - Benzinga

Anavex Life Sciences' Alzheimer's Candidate Mechanism Of Action Explained In Medical Journal

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that ANAVEX 2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeu...

3 months ago - Benzinga

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesin...

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

3 months ago - GlobeNewsWire

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) P...

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

3 months ago - GlobeNewsWire

Anavex Life Sciences (AVXL) Just Reclaimed the 50-Day Moving Average

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

3 months ago - Zacks Investment Research